L. S. Treyvish

L. S. Treyvish

Auto-generated profile, based on publicly available information

L. S. Treyvish

Clinical Hospital “Avicenna” of Group of Companies “Mother and Child

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2023 in Experimental and Сlinical Urology
Verified
Journal Article
Open access
EKE.V. Kulchavenya
E.V. Kulchavenya
LTL.S. Treyvish
L.S. Treyvish
ETE.V. Telina
E.V. Telina
RNRussia The Avicenna Medical Center; Novosibirsk
Russia The Avicenna Medical Center; Novosibirsk
DKD.P. Kholtobin
D.P. Kholtobin
RNRussia Municipal Clinic No. 26; Novosibirsk
Russia Municipal Clinic No. 26; Novosibirsk
Introduction. Asymptomatic bacteriuria (ABU) occurs in 2–15% of pregnant women, but opinions about ABU in pregnant women are controversial. The aim of the study was to assess the outcomes of delivery in pregnant women with ABU, depending on the therapy and urological history. Material and methods. The histories of childbirth of 46 women with ABU detected during prenatal screening, were analyzed. The outcomes of pregnancies were analyzed, and the relationship between the presence of ABU, the type of therapy, the presence of pyelonephritis in history and the development (exacerbation) of pyelonephritis during pregnancy was determined. Results. The structure of uropathogens was typical: E. coli was found in 36 cases (78.3%), Enterococcus faecalis - in 10 cases (21.7%). Seven women (15.2%) had a history of chronic pyelonephritis, 4 (8.7%) had chronic cystitis. The remaining 35 pregnant women (76.1%) had no any urological diseases. More than half of pregnant women with ABU (32/69.6%) received Сanephron; all of them had normal delivery. The average weight of newborns was 3768±101.9 grams. The rest of the 14 (30.4%) pregnant women with ABU, including 7 patients with a history of pyelonephritis, received amoxicillin with clavulonic acid. In more than half of the them (4/57.1%) gestational pyelonephritis developed. Correlational analysis showed that the low weight of the newborn, the development of gestational pyelonephritis and the likelihood of preterm birth did not depend on the therapy for ABU (antibacterial or herbal medicine), but on the presence of chronic pyelonephritis in the pregnant woman. Conclusion. The detection of ABU in a healthy pregnant woman without urological history is not a convincing basis for prescribing antibiotics. Preventive phytotherapy with the drug «Canephron» in such women was sufficient; none of the cases developed gestational pyelonephritis or preterm labor

17 January 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
EKE. V. Kulchavenya
E. V. Kulchavenya
LTL. S. Treyvish
L. S. Treyvish
VPV. V. Prokudina
V. V. Prokudina
An analytical review of domestic and foreign literature on the problem of osteoporosis was performed, and the principles of the approach to diagnosis and treatment of this disease are described.The probability of vertebral fracture should be assumed if there is a history of growth loss of 4 cm or more, the appearance of kyphosis in patients who received long-term therapy with glucocorticoids, with bone mineral density (BMD) less than 2.5 points In the treatment of patients with osteoporosis at the initial stage there is a tendency to limit oneself to non-drug measures, advising to change lifestyle and diet, to increase intake of vitamin D and calcium with food, to optimize physical activity. However, the main place in the prevention and treatment of osteoporosis in postmenopausal women is occupied by medication therapy, which can reduce the risk of fractures by 70%: bisphosphonates, drugs derived from parathyroid hormone, denosumab and selective estrogen receptor modulators. It is advisable to start therapy with oral bisphosphonates in most cases. They are powerful inhibitors of bone resorption and act by reducing the activity of osteoclasts and increasing their apoptosis. In 2020, the patent protection period of the main original bisphosphonates expired and generics of Russian production appeared: Rezoviva (ibandronic acid 3 mg for intravenous injection once every 3 months) and Osteostatix (zoledronic acid 5 mg 100 ml solution for intravenous drip once a year). After 3–5 years of bisphosphonate treatment, treatment should be reconsidered. The risk of recurrent fractures should be reassessed after the injury occurs. The risk of new fractures increases in patients who stop treatment. Study results have recommended ibandronate as a first-line drug in women with postmenopausal osteoporosis. Studies comparing intermittent intravenous ibandronate administration with daily oral treatment in women with postmenopausal osteoporosis allowed to recommend intravenous ibandronate at a dose of 3 mg every 3 months as the preferred therapy.

12 August 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
EKE. V. Kulchavenya
E. V. Kulchavenya
LTL. S. Treyvish
L. S. Treyvish
ETE. V. Telina
E. V. Telina
Worldwide, urinary tract infections (UTIs) are reported in 150-250 million people per year. Annual direct and indirect costs of UTIs for overall patients are estimated to be from $2.4 billion to $3.5 billion Uropathogenic Escherichia coli is the most common cause of UTIs. These bacteria have the ability to colonize urothelium, persist in epithelial cells, and form quiescent biofilms. This bacterial reservoir may provide a source for bacterial persistence and UTIs recurrence. Besides, recurrent UTIs may be caused by the translocation of other bacteria which originate from the gastrointestinal tract or reinfections due to external sources. Menopause and pregnancy are considered as complicating factors that predispose to UTIs. Oral vaccine OM-89 and D-mannose are specified in the European Urological Association guidelines among non-pharmacological methods for the prevention of recurrent UTIs in postmenopausal women. The rationale to the use of D-mannose in UTI prophylaxis is based on its competitive inhibition of bacterial adherence to urothelial cells due to binding of type 1 fimbriae expressed on the bacteria. Exogenous D-mannose is absorbed, but not metabolized by the human body and it is excreted intact in urine. In vivo and in vitro studies showed the ability of mannose-like molecules to provide a 2-fold reduction of bacterial load in the urinary tract after 4 intravesical instillations. Clinical studies also demonstrated a high efficacy of the six months course of oral mannose in the prevention of UTIs.

1 May 2024 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
EKE. V. Kulchavenya
E. V. Kulchavenya
DKD. P. Kholtobin
D. P. Kholtobin
EBE. V. Brizhatyuk
E. V. Brizhatyuk
SSS. Yu. Shevchenko
S. Yu. Shevchenko
LTL. S. Treyvish
L. S. Treyvish
ETE. V. Telina
E. V. Telina
Introduction. Urinary tract infections are the second most common type of bacterial infections worldwide. Treatment of patients with chronic (recurrent) cystitis remains challenging and requires an individual approach.Aim. To assess the efficacy of combined therapy for exacerbation of chronic cystitis.Materials and methods. A total of 65 women aged 18–48 years were enrolled in an open comparative bidirectional study. All participants received antibacterial therapy for exacerbation of chronic cystitis in accordance with the clinical guidelines for the treatment of cystitis in women. After the therapy was completed, the comparison group (35 patients) did not receive any drugs, whereas 30 patients from the treatment group were prescribed Cystenium II biologically active dietary supplement at a dose of 1 orally disintegrating tablet twice daily for 2 weeks. The examination included a measurement of the severity of complaints using the Acute Cystitis Symptom Score (ACSS), a clinical urinalysis and urine culture + sensitivity test. The efficacy of treatment was assessed following completion of antibiotic therapy and two weeks after the therapy.Results. After finishing antibiotic treatment, no patient has achieved full recovery (improvement of urinalyses, no growth of pathogenic microbial flora, no complaints). Both groups showed statistically significant decreases in ACSS scores on Visit 2. Over the following two weeks, the symptoms in the comparison group did not change (p > 0.05), and in the treatment group the sum of scores continued to decrease, reaching an average of 3.62 ± 0.42, which is 5.5 times less than the baseline level and almost 3 times less than the sum of scores following completion of antibacterial therapy (p < 0.05). The positive changes in leukocyturia and bacteriuria were also more pronounced in the treatment group.Conclusion. After completion of antibiotic therapy for relapse of chronic (recurrent) cystitis, the patients usually have residual effects that cannot be regarded as presentations of an active disease, but they disturb patients. A two-week course of pathogenetic therapy with a combination drug containing A-type Vaccinium macrocarpon proanthocyanidins, vitamin C and D-mannose to be received as the second step can increase the efficacy of treatment.

25 March 2025 in Experimental and Сlinical Urology
Verified
Journal Article
Open access
ATA.YU. Tsukanov
A.YU. Tsukanov
ISI.V. Savelyeva
I.V. Savelyeva
EKE.V. Kulchavenya
E.V. Kulchavenya
KIKh.S. Ibishev
Kh.S. Ibishev
MFM.A. Firsov
M.A. Firsov
LTL.S. Treyvish
L.S. Treyvish
Introduction. Asymptomatic bacteriuria (AB) is a form of urinary tract infection (UTI) that occurs without any symptoms. Its incidence fluctuates around 6%. The generally accepted paradigm suggests the need to treat AB, but this statement is mainly based on research data from the 1950-70 years. Objective. To study the effect of antimicrobial drugs in the treatment of AB in pregnant women on obstetric and perinatal outcomes and urological complications. Materials and methods. A multicenter retrospective study was conducted involving 182 pregnant women aged 18 to 45 years with established AB. During the study, the pregnant women were divided into 4 groups with different criteria; Group 1 (n=44) received treatment with protected penicillins; Group 2 (n=47) received treatment with fosfomycin; Group 3 (n=40) the drug of choice was cephalosporin; Group 4 (n=51) patients with normal pregnancy. Results. No significant differences were found in mean age, obstetric outcomes, and urological complications. Preterm birth was more common in Group 1 compared to Group 2, preeclampsia was also more common in Group 1, but Group 2 tended to have an increased incidence of the complication. Low fetal weight was more common in Group 1 and Group 3, but fetal hypoxia was more common in Group 2, and it was not possible to associate this complication with antibiotic use. Conclusion. Further studies are needed to assess both the association of AB in pregnant women with gestational pyelonephritis and to determine the benefits of prescribing antimicrobials for this type of UTI.

20 November 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Closed access
EKE. V. Kulchavenya
E. V. Kulchavenya
LTL. S. Treyvish
L. S. Treyvish
DKD. P. Kholtobin
D. P. Kholtobin
EBE. V. Brizhatyuk
E. V. Brizhatyuk
SSS. Yu. Shevchenko
S. Yu. Shevchenko
Introduction . Postcoital cystitis (PCC) is not placed in a separate form of the disease, but rather considered as an isolated case of chronic (recurrent) cystitis; there are no sound recommendations for its treatment. Aim. To determine the comparative efficacy of Furazidin and the combination of D-mannose and cranberry extract (Cystenium II supplement) in preventing recurrent PCC. Materials and methods . We observed 60 female patients with chronic recurrent cystitis, aged 18 to 50 years (mean age 31.2 ± 4.9 years). All female patients had at least two recurrences within the previous 6 months, experiencing at least every second episode of cystitis occurring within 2–24 hours after sexual intercourse. The patients were randomized into two groups of 30 patients each: a treatment group (TG) and a comparator group (CG). The TG patients received Cystenium II at a dose of one lozenge 30–120 minutes before sexual intercourse and 8–12 hours after intercourse. In the CG, patients received Furazidin at a dose of 50 mg 2 hours before or within 2 hours after sexual intercourse. Results. Both groups showed improvements during the therapy, but the severity of changes varied considerably. Upon completion of the treatment, the number of recurrences in the Cystenium Group was 9.5 times lower than in the Furazidin Group, while the number of sexual intercourses in the TG, in contrast, increased 1.5 times as compared to the CG. The proportion of sexual intercourses which resulted in PCC significantly reduced in both groups: from 63.6% to 2.8% in the TG and from 62.8% to 38% in the CG. The difference between the groups was statistically significant. Conclusion. The results of this study clearly showed that Cystenium II supplement taken twice daily was more effective and better tolerated than Furazidin at a single paracoital dose of 50 mg to prevent recurrent PCC.